Brief: Kineta Unveils Positive New Data from VISTA-101 Clinical Trial of KVA12123
06/11/2023 14:17
Nov 6 (Reuters) - Kineta Inc KA.O :
* KINETA UNVEILS POSITIVE NEW DATA FROM VISTA-101 CLINICAL
TRIAL
OF KVA12123 AT THE SOCIETY FOR IMMUNOTHERAPY OF CANCER’S (SITC)
38TH ANNUAL MEETING
* KINETA INC - FAVORABLE CLINICAL SAFETY AND TOLERABILITY
PROFILE
OBSERVED WITH NO EVIDENCE OF CRS-ASSOCIATED CYTOKINES
* KINETA INC - ACHIEVED GREATER THAN DOSE-PROPORTIONAL
PHARMACOKINETICS
* KINETA INC - BIOMARKER RESULTS DEMONSTRATE ROBUST VISTA
TARGET
ENGAGEMENT
* KINETA INC - ADDITIONAL MONOTHERAPY AND COMBINATION
THERAPY
CLINICAL DATA ANTICIPATED IN Q2 2024
* KINETA INC - KVA12123 WAS WELL TOLERATED AT ALL DOSES AND
NO
DOSE LIMITING TOXICITIES (DLT) WERE OBSERVED
Source text for Eikon: ID:nGNX7WRRL7
Further company coverage: KA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Kineta
See all newsBrief: TuHURA Biosciences And Kineta Stockholders Approve Proposed Merger And All Related Proposals
Brief: Kineta Updates KVA12123 Clinical Results From Ongoing Phase 1/2 Vista101 Study At Society For Immunotherapy Of Cancer
U.S. STOCKS ON THE MOVE-Copper miners, Palo Alto Networks, Lowe's
U.S. STOCKS ON THE MOVE-Lineage, J.B. Hunt, McDonald's
Kineta rises on resuming enrollment in early-stage cancer study